Literature for verubecestat (A01.004 inhibitor)

(Topics flags: I Inhibitor. To select only the references relevant to a single topic, click the link above. See explanation.)

2019
1. Panza,F., Lozupone,M., Watling,M. and Imbimbo,B.P.
   Do BACE inhibitor failures in Alzheimer patients challenge the amyloid hypothesis of the disease?
   Expert Rev Neurother19, 599-602. PubMed  Europe PubMed DOI  I
2. Selkoe,D.
   beta-Secretase inhibitors for Alzheimer's disease: heading in the wrong direction?
   Lancet Neurol18, 624-626. PubMed  Europe PubMed DOI  I
2016
3. Kennedy,M.E., Stamford,A.W., Chen,X., Cox,K., Cumming,J.N., Dockendorf,M.F., Egan,M., Ereshefsky,L., Hodgson,R.A., Hyde,L.A., Jhee,S., Kleijn,H.J., Kuvelkar,R., Li,W., Mattson,B.A., Mei,H., Palcza,J., Scott,J.D., Tanen,M., Troyer,M.D., Tseng,J.L., Stone,J.A., Parker,E.M. and Forman,M.S.
   The BACE1 inhibitor verubecestat (MK-8931) reduces CNS beta-amyloid in animal models and in Alzheimer's disease patients
   Sci Transl Med8, 363ra150-363ra. PubMed  Europe PubMed DOI  I
4. Scott,J.D., Li,S.W., Brunskill,A.P., Chen,X., Cox,K., Cumming,J.N., Forman,M., Gilbert,E.J., Hodgson,R.A., Hyde,L.A., Jiang,Q., Iserloh,U., Kazakevich,I., Kuvelkar,R., Mei,H., Meredith,J., Misiaszek,J., Orth,P., Rossiter,L.M., Slater,M., Stone,J., Strickland,C.O., Voigt,J.H., Wang,G., Wang,H., Wu,Y., Greenlee,W.J., Parker,E.M., Kennedy,M.E. and Stamford,A.W.
   Discovery of the 3-imino-1,2,4-thiadiazinane 1,1-dioxide derivative verubecestat (MK-8931)-a beta-site amyloid precursor protein cleaving enzyme 1 inhibitor for the treatment of Alzheimer's disease
   J Med Chem59, 10435-10450. PubMed  Europe PubMed DOI  I
2014
5. 
   The BACE race is on
   Nat Rev Drug Discov13, 165-165. DOI  I
6. Menting,K.W. and Claassen,J.A.
   beta-secretase inhibitor; a promising novel therapeutic drug in Alzheimer's disease
   Front Aging Neurosci6, 165-165. PubMed  Europe PubMed DOI  I